Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biotechnology company based in Jerusalem, Israel, incorporated in 2009. It develops oral peptide and protein replacement therapies. Its pipeline includes EB613, an oral teriparatide that completed Phase II trials for osteoporosis and Phase I trials for stress fractures; EB612, a tablet peptide replacement therapy in Phase I for hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide in Phase I for obesity, metabolic, and fibrotic disorders; and GLP-2 in Phase I for short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. The company has a collaboration agreement with OPKO Biologics, Inc. for the preclinical and clinical development of LA-PTH and an oral dual agonist GLP-1/glucagon peptide.